World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 19 February 2015
Main ID:  NCT01817426
Date of registration: 29/08/2012
Prospective Registration: Yes
Primary sponsor: Copenhagen University Hospital at Herlev
Public title: Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission STOP IT
Scientific title: Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study
Date of first enrolment: November 2012
Target sample size: 136
Recruitment status: Recruiting
Study type:  Interventional
Study design:  Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment  
Phase:  Phase 4
Countries of recruitment
Name:     Sine Schnoor Buhl, M.D.
Telephone: +45 51201207
Name:     Mark Ainsworth, MD.PHD.,DMSc
Affiliation:  Herlev Hospital, dep. of gastroenterology medical section.
Key inclusion & exclusion criteria

Inclusion Criteria:

- Luminal Crohn's disease defined according to standardized diagnostic criteria.

- Age = 18 years.

- IFX induction treatment week 0, 2, 6 followed by maintenance therapy.

- IFX treatment length minimum 12 months. Episodic therapy with IFX pause > 12 weeks is
not accepted within the last year. The treatment interval in the last three months
has to be of 6-10 weeks.

- Complete remission defined as:

- CDAI score < 150 and

- Biochemical remission, and

- No other signs of disease activity as evaluated by endoscopic examination or by
magnetic resonance imaging (MRI).

- Stable remission, judged by the treating physician, at two consecutive treatments
visits corresponding 2 scheduled IFX infusions. Thus, the first visit is during IFX
maintaining therapy (screening visit). The second visit is at time of inclusion
corresponding time of next scheduled IFX infusion (i.e. after ˜ 8 weeks).

- No use of oral steroids within 3 months prior to inclusion.

- Concomitant therapy with other immune suppressants, except steroids, is allowed. The
dosage and frequency must have been stable three months prior to inclusion and must
remain stable throughout the study period.

Exclusion Criteria:

- Initial indication for IFX being predominantly fistulizing perianal disease.

- Any contraindications for continuing IFX treatment, including prior acute or delayed
infusion reaction to a TNF- inhibiting agent, any active infection requiring
parenteral or oral antibiotic treatment, known infection with tuberculosis, human
immunodeficiency virus (HIV) or hepatitis virus.

- Any condition including physician finds incompatible with participation in the study
or the patient being unwilling or unable to follow protocol requirements.

Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Crohn Disease
Drug: Infliximab
Other: Placebo
Primary Outcome(s)
Proportion of patients who maintain remission, i.e. CDAI <150 [Time Frame: 48 weeks]
Secondary Outcome(s)
Change from baseline in disease activity. [Time Frame: 48 weeks]
Direct medical costs in the to groups [Time Frame: 48 weeks]
Median time to relapse after discontinuation of IFX [Time Frame: 48 weeks]
Proportion of patients experiencing relapse [Time Frame: 48 weeks]
Proportion of patients who maintain complete remission [Time Frame: 48 weeks]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history